Neurogene Inc. cotiza a 22.06 USD y tiene una capitalización bursátil de $441M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene t…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-1.13 | $-0.99 |
| Estimado | $-1.45 | $-1.37 | $-1.24 | $-1.09 |
| Sorpresa | — | — | +8.9% | +9.2% |
| Métrica | NGNE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -34.1% | -40.4% | +6.3% |
| ROA | -31.3% | -32.0% | +0.7% |
| Current Ratio | 16.56 | 2.84 | +13.72 |
| Debt / Equity | — | 0.28 | — |